Author

Vanessa M. Kelley

Yale UniversityORCID 0000-0002-1734-3734Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

Chatchai PhoomakiD· 2 shared Joseph N. ContessaiD· 2 shared Marta BaroiD· 2 shared Caroline J. ZeissiD· 1 shared Hannah G. LeaiD· 1 shared Hojin LeeiD· 1 shared Hojin LeeiD· 1 shared Katerina A. PolitiiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Chatchai PhoomakORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyCancer ResearchPeer-reviewedJan 27, 2026

Loss of JAK1 Function Causes G2/M Cell Cycle Defects Vulnerable to Kif18a Inhibition

Vanessa M. Kelley, Marta Baro, William E. Gasperi…·Joseph N. Contessa

This study identifies JAK1 as a driver of tumor cell radiosensitivity and shows that Kif18a inhibition can counteract therapeutic resistance by exacerbating mitotic stress.

3 citationstop 4%

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyCell chemical biologyPeer-reviewedDec 5, 2024

OST Catalytic Subunit Redundancy Enables Therapeutic Targeting of N-Glycosylation

Marta Baro, Hojin Lee, Vanessa M. Kelley…·Joseph N. Contessa

The paper develops OST inhibitors that selectively target STT3A and STT3B, leading to tumor regression in EGFR-mutant lung cancer models.

7 citations

humanproteomics

𝕏 PostBluesky